Anti-EGFR antibody-drug conjugates reported in Hutchmed patent

May 28, 2026

Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases.

BioWorld Science Cancer Antibody-drug conjugate Immuno-oncology Patents

Today's news in brief

BioWorld

BioWorld briefs for June 15, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...